Parkinson Disease

The director of the Center for Neurological Restoration at Cleveland Clinic discussed long-term TEMPO-4 data evaluating tavapadon’s impact on symptom control and levodopa utilization in Parkinson disease.

A duo of Baptist Health experts discussed emerging evidence suggesting that hormonal factors, sex-based clinical differences, and social roles contribute to distinct experiences for women with Parkinson disease.

A recent study suggested that probiotic regimens and biomarker-guided strategies may be a promising signal for reducing excessive daytime sleepiness in patients with PD and CKD.

New findings from a post hoc analysis of 2 phase 3 trials, presented at AAN 2026, reported that a majority of participants with advanced Parkinson disease had no troublesome dyskinesia at follow-up.

The president at Cala Health discussed the clinical role, evidence base, and future potential of the Cala kIQ Plus wearable TAPS therapy for patients with essential tremor and Parkinson disease at AAN 2026.

Real-world data of the ELEVATE-PD study, presented at AAN 2026, suggest that switching to IPX203 from other levodopa-based therapies may improve motor function in patients with Parkinson disease.

In recognition of National Public Health Week, held April 6-12, NeurologyLive summarizes recent literature showing that environmental exposures are associated with increased risk of neurologic disorders.

In a preclinical study, subthalamic nucleus (STN) low-beta power negatively correlated with wake quantity, whereas STN and motor cortex high-beta power demonstrated a positive correlation with wakefulness.

A new retrospective analysis presented at AD/PD 2026 showed that cutaneous phosphorylated α-synuclein testing reduced diagnostic and management-related health care expenditures.

An analysis of baseline data from the phase 2b LUMA study suggested that keystroke dynamics captured through a smartphone-based typing task could provide a reliable method for assessing disease progression in Parkinson disease.

Early ASPIRO trial data show autologous stem-cell dopamine precursors stay safe at 12 months, with improved PD motor scores and PET-confirmed grafting.

UK platform trial enrolls 1,600 with Parkinson’s to rapidly test telmisartan, terazosin and new candidates via shared placebo and virtual visits.

Xenos Mason, MD, a neurologist specializing in movement disorders, provides commentary on an early-stage study evaluating induced pluripotent stem cells for patients with Parkinson disease.

A phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.

Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Parkinson disease that may impact care.

Margaret Rice, PhD, a professor in the Departments of Neurosurgery and Neuroscience at NYU Grossman School of Medicine, provided answers on recently published preclinical research relating aerobic exercise to dopamine release and coordination in PD.

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

At MDS 2025, the professor of neurology at Northwestern University Feinberg School of Medicine discussed the evolving landscape of disease-modifying clinical trials in Parkinson disease.

Jupiter Neurosciences advances Parkinson treatment with FDA clearance for JOTROL's phase 2a trial, showcasing promising safety and bioavailability results.

A post-hoc analysis study revealed apomorphine sublingual film was efficacious over a long term period across various age ranges, including elders, with Parkinson disease.

Mark Forman, MD, PhD, chief medical officer at Ventyx Biosciences, discussed promising early-stage data of VTX3232, an NLRP3 inflammasome in development for early-stage Parkinson disease.

Clinical trial data presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders showed that pimavanserin had positive efficacy in patients showing Parkinson Disease psychosis symptoms who were treated earlier.

Late breaking data from a phase 1 trial presented at MDS 2025 showed that cell therapy UX-DA001 demonstrated positive efficacy in a woman with moderate-to-advanced Parkinson disease.